Updated:
Inotiv
Inotiv (NASDAQ: NOTV) is a publicly traded CRO providing nonclinical drug discovery, development services, and research models including nonhuman primates.
Inotiv
Inotiv provides nonclinical and analytical drug discovery and development services, research models and related products and services.
General information
Firm type
other
Location
Region
North America
Country
United States
City
West Lafayette
Corporate office
West Lafayette, IN, United States
Sector focus
Frequently asked questions
Who leads Inotiv as CEO?
Inotiv's leadership is listed on its website but named individuals were not captured in the available source material. The company is publicly traded, so its CEO is disclosed in SEC filings.
How does Inotiv generate revenue?
Inotiv generates revenue through two segments: Discovery and Development Services (nonclinical safety assessment, bioanalysis, toxicology) and Research Models and Services (sale of rodents, rabbits, nonhuman primates, and related services like contract breeding and surgical support).
Is Inotiv a family office?
No. Inotiv is a publicly traded contract research organization (NASDAQ: NOTV). It does not manage wealth for a single family or group of families.
What is the significance of Inotiv being publicly traded?
Being publicly traded means Inotiv files quarterly and annual reports with the SEC, discloses executive compensation, and is subject to shareholder scrutiny. This sets it apart from privately held CROs and gives allocators access to standardized financial data.
Did Inotiv experience a cybersecurity incident?
Yes. In February 2026, Inotiv disclosed a cybersecurity incident that affected certain systems (per the firm, February 2026). The company provided a substitute notice on its website.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: